Stefano Buono

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer

Retrieved on: 
Tuesday, December 5, 2023
Pfizer, MIT, CSO, Patient, Kling, Infection, Therapy, Massachusetts Institute of Technology, Drug discovery, Cancer, Agenus, Stefano Buono, Autoimmunity, Pharmaceutical industry, Northeastern University, Science, Biochemistry

AMSTERDAM, Dec. 5, 2023 /PRNewswire/ -- Kling Bio ("Kling" or "the Company"), a biotech company developing antibody-based drugs against targets identified from its immortalized B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as Chief Scientific Officer.

Key Points: 
  • AMSTERDAM, Dec. 5, 2023 /PRNewswire/ -- Kling Bio ("Kling" or "the Company"), a biotech company developing antibody-based drugs against targets identified from its immortalized B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as Chief Scientific Officer.
  • Dr Gullà is a seasoned industry veteran with over 15 years of experience in biotherapeutics discovery and development.
  • Commenting on the appointment, Michael Koslowski, Chief Executive Officer of Kling Bio, said: "Kling will benefit immensely from Stefano's proven leadership skills and in-depth scientific knowledge.
  • Stefano Gullà, new Chief Scientific Officer of Kling Bio, commented: "Kling's technology is a powerful discovery engine that enables simultaneous and unbiased identification of new targets and therapeutic antibodies.

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer

Retrieved on: 
Tuesday, December 5, 2023
Pfizer, MIT, CSO, Patient, Kling, Infection, Therapy, Massachusetts Institute of Technology, Drug discovery, Cancer, Agenus, Stefano Buono, Autoimmunity, Pharmaceutical industry, Northeastern University, Science, Biochemistry

AMSTERDAM, Dec. 5, 2023 /PRNewswire/ -- Kling Bio ("Kling" or "the Company"), a biotech company developing antibody-based drugs against targets identified from its immortalized B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as Chief Scientific Officer.

Key Points: 
  • AMSTERDAM, Dec. 5, 2023 /PRNewswire/ -- Kling Bio ("Kling" or "the Company"), a biotech company developing antibody-based drugs against targets identified from its immortalized B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as Chief Scientific Officer.
  • Dr Gullà is a seasoned industry veteran with over 15 years of experience in biotherapeutics discovery and development.
  • Commenting on the appointment, Michael Koslowski, Chief Executive Officer of Kling Bio, said: "Kling will benefit immensely from Stefano's proven leadership skills and in-depth scientific knowledge.
  • Stefano Gullà, new Chief Scientific Officer of Kling Bio, commented: "Kling's technology is a powerful discovery engine that enables simultaneous and unbiased identification of new targets and therapeutic antibodies.